Combination antiretroviral drugs in PLGA nanoparticle for HIV-1

Combination antiretroviral drugs in PLGA nanoparticle for HIV-1

BACKGROUND Combination antiretroviral (AR) therapy continues to be the mainstay for HIV treatment. However, antiretroviral drug nonadherence can lead to the development of resistance and treatment failure. We have designed nanoparticles (NP) that contain three AR drugs and characterized the size, shape, and surface charge. Additionally, we investigated the in vitro release of the AR drugs from ...

Drug-Resistant HIV-1 RT Gene Mutations in Patients under Treatment with Antiretroviral Drugs (HAART) in Iran

Abstract Background and Objective: Highly Active Antiretroviral Therapy (HAART) can effectively prevent the progression of HIV-1 replication and increase life expectancy. There are numerous causes of treatment failure and the leading one is drug resistance. Thus, we aimed to determine the HIV RT gene drug resistance mutations in patients treated with antiretroviral medications. Material...

Clinical Guidelines: Antiretroviral Drugs for Hiv Prevention

Maternal or infant antiretroviral drugs to reduce HIV-1 transmission.

BACKGROUND We evaluated the efficacy of a maternal triple-drug antiretroviral regimen or infant nevirapine prophylaxis for 28 weeks during breast-feeding to reduce postnatal transmission of human immunodeficiency virus type 1 (HIV-1) in Malawi. METHODS We randomly assigned 2369 HIV-1-positive, breast-feeding mothers with a CD4+ lymphocyte count of at least 250 cells per cubic millimeter and t...

Too bad! Fixed dose combination antiretroviral drugs

Materials and methods 1681 HIV positive patients accessing care at Suntreso STI/HIV Clinic in Kumasi, who have been on treatment for more than 12 months and consented to participate were recruited for this cross sectional study. They were interviewed using semi-structured pre-texted questionnaire prior to the commencement of the new fixed dose combination ARVs treatment regime. Data was entered...